| Literature DB >> 30065619 |
Zhi-Xia Yue1,2, Rui-Qi Gao3, Chao Gao2, Shu-Guang Liu2, Xiao-Xi Zhao2, Tian-Yu Xing2, Jing Niu3,4, Zhi-Gang Li5, Hu-Yong Zheng2, Wei Ding3,4.
Abstract
BACKGROUND: Cajal body (CB) is a nucleic organelle where small nuclear ribonucleoproteins undergo modification, maturation, splicing and/or assembly. Coilin is the marker structural protein of CBs. The expression level and cellular localization of coilin is sensitive to chemotherapeutic reagents, such as cisplatin. The gene of cyclin-dependent kinase inhibitor 1B (p27) is located with a high incidence translocation region of leukemic chromosomes, and its expression was of prognosis values in a variety of adult leukemia types. The exact profile and associated functions of coilin, as well as p27, in children's acute lymphoblastic leukemia (ALL) is obscure.Entities:
Keywords: Acute lymphoblastic leukemia; Chemotherapy; Coilin; Pediatrics; Relapse; p27
Year: 2018 PMID: 30065619 PMCID: PMC6062948 DOI: 10.1186/s12935-018-0600-5
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
Clinical information and statistics about the included 144 patients
| Characteristics | Total (n %) |
|---|---|
| Gender | |
| Male | 86 (59.7) |
| Female | 58 (40.3) |
| Age (years) | |
| 1–9 | 124 (86.1) |
| ≥ 10 | 20 (13.9) |
| Median | 4.1 |
| Range | 0.5–14.9 |
| WBC (× 109/l) | |
| < 50 | 123 (85.4) |
| ≥ 50 | 21 (14.6) |
| Median | 8.3 |
| Range | 1.1–990.0 |
| CNS involvement | |
| No | 143 (99.3) |
| Yes | 1 (0.7) |
| Fusion gene | |
| | 30 (20.8) |
| | 8 (5.6) |
| | 10 (6.9) |
| | 6 (4.2) |
| Others | 2 (1.4) |
| Prednisone response | |
| Good | 137 (95.1) |
| Poor | 7 (4.9) |
| MRD at day 33 | |
| < 1 × 10−4 | 38 (26.4) |
| ≥ 1 × 10−4 | 106 (73.6) |
| Treatment outcome | |
| Relapse | 13 (9.1) |
| Death | 11 (7.6) |
| CCR | 120 (83.3) |
| Survival (%) | |
| 4-year EFS | 83.1 ± 3.1 |
WBC white blood cell, CNS central nervous system, MRD minimal residual disease, CCR continuous complete remission, EFS event-free survival
Fig. 1Subcellular localization and expression of coilin in leukemia cells following DNR treatments. Immunofluorescence of coilin in Reh (a) and RS4;11 (b) cells treated with different doses of DNR for 24 h. The nuclei were post-stained in blue with 4′,6-diamino-2-phenylindole (DAPI). c Immunofluorescence of coilin in Reh cells treated with arabinocytidine (AraC, 30 μg/ml), Vincristine (VCR, 1.5 μg/ml) or adriamycin (ADR, 2.0 μg/ml). d Coilin expression at the mRNA in Reh cells treated with DNR (0.03 μg/ml) for 24 h. Compared with the non-treated control, a significant increase (*p = 0.002, n = 3) was observed from the RT-qPCR measures. e Coilin expression at protein levels in Reh cells treated with DNR (0.03 μg/ml) for 24 h. Quantification from the Western blot of coilin (*p = 0.025) and γH2AX (*p = 0.003) also indicated increased levels normalized to GAPDH (n = 3)
Fig. 2The coilin mRNA levels from the bone marrow samples in different clinical subgroups of pediatric ALL. a Relative coilin mRNA levels at diagnosis (day 0) or complete remission (day 78) (n = 22). b Coilin expression in patients of continuous complete remission (CCR) (n = 120) or disease relapse (n = 13)
Fig. 3Effects of coilin knockdown in leukemia cells following DNR (0.03 μg/ml) treatments. a Flow cytometry analyses for apoptosis in Reh cells infected with a lenti-virus expressing a scrambled control or a shRNA targeting coilin. b Quantification on apoptosis (*p = 0.019, n = 3) from cells subjected to the same treatments as in a. c The cell survival measures in sh-Coilin infected Reh cells without or with DNR treatments (*p = 0.002, #p = 0.014, n = 3). d Western blot of p27 and γH2AX from leukemia cells treated with DNR (0.03 μg/ml). Quantification (n = 3) of coilin, p27 and γH2AX proteins relative to GAPDH levels. The expression of coilin and p27 were decreased (*p = 0.009, p = 0.044); whereas γH2AX was increased (*p = 0.001)
Fig. 4Expression of p27 in different subgroups conjoining coilin levels for the prognosis of pediatric BCP-ALL. a Relative p27 expression at diagnosis (day 0) or complete remission (day 78) (n = 22). b Levels of p27 expression in patients of continuous complete remission (CCR) (n = 120) or relapse (n = 13). Analyses of c event free survival (EFS) and d relapse free survival (RFS) from the whole cohort of 144 BCP-ALL patients with high or low coilin expression. Analyses of e event free survival (EFS) and f relapse free survival (RFS) in patients with high or low p27 expression